A multicenter, randomized double-blind phase II/III study in the first-line treatment of advanced transitional cell carcinoma (TCC) of the urothelium comparing vinflunine/gemcitabine to placebo/gemcitabine in patients who are ineligible to receive cisplatin-based therapy.

Trial Profile

A multicenter, randomized double-blind phase II/III study in the first-line treatment of advanced transitional cell carcinoma (TCC) of the urothelium comparing vinflunine/gemcitabine to placebo/gemcitabine in patients who are ineligible to receive cisplatin-based therapy.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 09 Dec 2015

At a glance

  • Drugs Gemcitabine; Vinflunine
  • Indications Bladder cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms VINCENT
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 30 Jun 2012 Planned number of patients changed from 450 to 500 as reported by European Clinical Trials Database record.
    • 25 Sep 2008 Status changed from active, no longer recruiting to completed.
    • 09 May 2008 The expected completion date for this trial has changed from 1 Oct 210 to 1 Sep 2008 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top